PE20181376A1 - Analogos del egf(a) con sustituyentes de acidos grasos - Google Patents

Analogos del egf(a) con sustituyentes de acidos grasos

Info

Publication number
PE20181376A1
PE20181376A1 PE2018001257A PE2018001257A PE20181376A1 PE 20181376 A1 PE20181376 A1 PE 20181376A1 PE 2018001257 A PE2018001257 A PE 2018001257A PE 2018001257 A PE2018001257 A PE 2018001257A PE 20181376 A1 PE20181376 A1 PE 20181376A1
Authority
PE
Peru
Prior art keywords
egf
fatty acid
bond
analogs
yglu
Prior art date
Application number
PE2018001257A
Other languages
English (en)
Inventor
Jianhe Chen
Jesper F Lau
Janos Tibor Kodra
Birgit Wieczorek
Lars Linderoth
Henning Thøgersen
Salka Elbøl Rasmussen
Patrick William Garibay
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PE20181376A1 publication Critical patent/PE20181376A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/485Epidermal growth factor [EGF], i.e. urogastrone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a un derivado de EGF(A) que comprende un analogo peptidico de EGF(A) del dominio EGF(A) de LDL-R definido por la SEC No. ID 1, que comprende 301 Leu y un sustituyente que comprende al menos un grupo de acido graso, como, por ejemplo, acido carboxilico, acido sulfonico, resto tetrazol, resto metilsulfonilcarbamoilamino, entre otros. Este sustituyente tiene la formula I, en donde Z1 se selecciona de: HOOC-(CH2)n-CO- , tetrazolil-(CH2)n-CO- , entre otros; Z2 es -NH-SO2-(CH3)3-CO- , entre otros; Z3 es yGlu, Glu o un enlace; Z4-Z5-Z6-Z7-Z8-Z9 se seleccionan de Glu, yGlu, Gly, Ser, Ala, Thr, Ado, Aeep, Aeeep, TtdSuc y un enlace; Z10 se selecciona de -NH-CH2-(C6H4)-CH2 y un enlace. Estos compuestos son utiles para el tratamiento de la hiperlipidemia, dislipidemia y enfermedad cardiovascular.
PE2018001257A 2016-01-13 2017-01-13 Analogos del egf(a) con sustituyentes de acidos grasos PE20181376A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016070791 2016-01-13
CN2016076580 2016-03-17
EP16195965 2016-10-27

Publications (1)

Publication Number Publication Date
PE20181376A1 true PE20181376A1 (es) 2018-09-05

Family

ID=57868232

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001257A PE20181376A1 (es) 2016-01-13 2017-01-13 Analogos del egf(a) con sustituyentes de acidos grasos

Country Status (26)

Country Link
US (2) US10822385B2 (es)
EP (1) EP3402811B1 (es)
JP (2) JP6797926B2 (es)
KR (1) KR102417487B1 (es)
CN (1) CN108473550B (es)
AU (1) AU2017207862B2 (es)
BR (1) BR112018013820A2 (es)
CA (1) CA3010756A1 (es)
CL (1) CL2018001868A1 (es)
CO (1) CO2018007440A2 (es)
DK (1) DK3402811T3 (es)
ES (1) ES2916998T3 (es)
HR (1) HRP20220720T1 (es)
HU (1) HUE058647T2 (es)
IL (1) IL260043A (es)
LT (1) LT3402811T (es)
MX (1) MX2018008681A (es)
MY (1) MY195199A (es)
PE (1) PE20181376A1 (es)
PH (1) PH12018501502A1 (es)
PL (1) PL3402811T3 (es)
RS (1) RS63298B1 (es)
RU (1) RU2747877C2 (es)
SA (1) SA518391996B1 (es)
SI (1) SI3402811T1 (es)
WO (1) WO2017121850A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049813T2 (hu) 2016-01-13 2020-10-28 Gruenenthal Gmbh 3-((hetero-)aril)-alkil-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-dekán származékok
DK3402811T3 (da) 2016-01-13 2022-06-13 Novo Nordisk As Egf(a)-analoger med fedtsyresubstituenter
CA3011182A1 (en) 2016-01-13 2017-07-20 Grunenthal Gmbh 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EA034904B1 (ru) 2016-01-13 2020-04-03 Грюненталь Гмбх Производные 3-(карбоксиметил)-8-амино-2-оксо-1,3-диазаспиро-[4.5]-декана
WO2017121647A1 (en) 2016-01-13 2017-07-20 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
CA3068956A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds
MA49617A (fr) * 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées
WO2019023295A1 (en) * 2017-07-27 2019-01-31 Saint Louis University HUMAN EPIDERMAL GROWTH FACTOR MODIFIED BY FATTY ACID
AR116605A1 (es) 2018-10-05 2021-05-26 Novo Nordisk As Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
CA3131997A1 (en) 2019-03-22 2020-10-01 3M Innovative Properties Company Fall-protection system with monitoring system
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
US20220323544A1 (en) 2019-08-07 2022-10-13 Novo Nordisk A/S Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
IL291893A (en) 2019-11-07 2022-06-01 Novo Nordisk As Solid preparations comprising a pcsk9 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino) caprylic acid
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909823A2 (en) 2005-07-29 2008-04-16 Amprotein Corporation Chimeric therapeutic agents
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー/エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
MX2010011499A (es) 2008-04-23 2010-11-12 Amgen Inc Variantes de proproteina neutralizante de convertasa subtilisina kexina de tipo 9 (pcsk9) y sus usos.
WO2009143633A1 (en) 2008-05-30 2009-12-03 Institut De Recherches Cliniques De Montreal Pcsk9 inhibitors and methods of use thereof
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9拮抗劑類
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
JPWO2012017774A1 (ja) * 2010-08-02 2013-10-03 日本電気株式会社 偏光子及び発光装置
CN102153652A (zh) 2010-12-10 2011-08-17 浙江大学 一种融合蛋白的表达方法及用途
WO2012110422A1 (en) 2011-02-15 2012-08-23 Novo Nordisk A/S Long-acting il-1 receptor antagonists
JP2014519848A (ja) * 2011-06-20 2014-08-21 ジェネンテック, インコーポレイテッド Pcsk9結合ポリペプチドと使用方法
TWI596110B (zh) * 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
US20140357838A1 (en) * 2011-12-21 2014-12-04 Novo Nordisk A/S N-Terminally Modified Insulin Derivatives
CN112142855A (zh) 2012-05-18 2020-12-29 爱德迪安(北京)生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
AR092076A1 (es) 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
CN104736558A (zh) 2012-09-07 2015-06-24 赛诺菲 用于治疗代谢综合征的融合蛋白
AU2014255608B2 (en) * 2013-04-18 2018-01-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
CA2935285A1 (en) 2014-02-21 2015-08-27 Medimmune, Llc Anti-pcsk9-glp-1 fusions and methods for use
CN106536547A (zh) * 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
CA2979617C (en) * 2015-03-19 2024-01-02 Institut De Cardiologie De Montreal Grp94 derived polypeptides for inhibiting pcsk9 and methods of use
CN105367884A (zh) 2015-11-02 2016-03-02 陈薇 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法
DK3402811T3 (da) 2016-01-13 2022-06-13 Novo Nordisk As Egf(a)-analoger med fedtsyresubstituenter
MA49617A (fr) 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées
CA3068956A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds

Also Published As

Publication number Publication date
ES2916998T3 (es) 2022-07-06
RS63298B1 (sr) 2022-07-29
US20190016768A1 (en) 2019-01-17
CN108473550B (zh) 2022-11-22
EP3402811B1 (en) 2022-03-30
AU2017207862B2 (en) 2020-12-17
SI3402811T1 (sl) 2022-06-30
AU2017207862A1 (en) 2018-07-05
US20200407409A1 (en) 2020-12-31
RU2018127882A (ru) 2020-02-13
PH12018501502A1 (en) 2019-03-25
HRP20220720T1 (hr) 2022-09-30
WO2017121850A1 (en) 2017-07-20
JP2019505521A (ja) 2019-02-28
MX2018008681A (es) 2018-09-17
JP2021035989A (ja) 2021-03-04
MY195199A (en) 2023-01-11
DK3402811T3 (da) 2022-06-13
SA518391996B1 (ar) 2021-07-14
KR102417487B1 (ko) 2022-07-06
CA3010756A1 (en) 2017-07-20
JP6797926B2 (ja) 2020-12-09
KR20180100177A (ko) 2018-09-07
EP3402811A1 (en) 2018-11-21
IL260043A (en) 2018-07-31
CO2018007440A2 (es) 2018-09-28
CL2018001868A1 (es) 2018-08-31
US10822385B2 (en) 2020-11-03
RU2018127882A3 (es) 2020-06-19
PL3402811T3 (pl) 2022-07-11
HUE058647T2 (hu) 2022-09-28
LT3402811T (lt) 2022-06-10
RU2747877C2 (ru) 2021-05-17
BR112018013820A2 (pt) 2018-12-11
CN108473550A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
PE20181376A1 (es) Analogos del egf(a) con sustituyentes de acidos grasos
CU24643B1 (es) Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47
PE20181045A1 (es) Compuestos utiles como inmunomoduladores
CU20170073A7 (es) Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos
AR115131A1 (es) Altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)
CL2020002224A1 (es) Agonistas de fenilpirrolidinona del receptor 2 de formil péptido
CU20190069A7 (es) Compuestos químicos derivados sustituidos de 1h-pirrolo[2,3-b] piridina como moduladores del receptor de hidrocarburos de arilo (ahr)
UY37169A (es) Análogos de 1,4-dihidropirimidin-5-carboxamidas como agonistas de apj y composiciones que los contienen
ES2691091T3 (es) Vacuna conjugada de péptido antigénico de WT1
PE20220488A1 (es) Variantes del cnp y sus conjugados
CU20190067A7 (es) Compuestos químicos derivados sustituidos de 1h-pirrolo [3,2-c] piridinas como moduladores del receptor de hidrocarburos de arilo (ahr)
MY195933A (en) Method for Purification of Animal or Vegetable Fats
MX2020008265A (es) Derivados farmaceuticos del anillo heterobiciclico 6,5.
CO2022001316A2 (es) Conjugados peptídicos de citotoxinas como terapéuticos
AR069437A1 (es) Bisfosfonatos de alquilo de 2 a 5 atomos de carbono - imidazol
CL2018003121A1 (es) Inhibidores del potenciador del homólogo zeste 2.
EA201992226A1 (ru) Агонисты npra, композиции и их использование
PE20200720A1 (es) Compuestos bifuncionales
CR20180560A (es) Ésteres de oxaboral y sus usos
BR112019008453A2 (pt) composições de polímero com plastificante de pbsa
EA201792640A1 (ru) Устойчивые к действию протеазы липидированные аналоги glp-1
PH12020550947A1 (en) Polymorphs
PE20181355A1 (es) Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
BR112021026061A2 (pt) Método para o tratamento de uma composição que compreende vanilina natural
CR20110305A (es) Péptidos antagonistas de crhr2 y usos de estos